Compare Cassava Sciences Inc (FLNA) vs SoFi Technologies Inc (SOFI) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

SOFI stock trades at $17.60, down 5.12% on the day, reflecting recent market pressures. The technical outlook is neutral with mixed signals, while fundamentals show robust revenue growth to $3.61 billion in 2025 and consistent earnings beats. Analyst sentiment is divided with a consensus price target of $22.43, but the stock faces headwinds from negative operating cash flow and high valuation multiples.

The investment case hinges on SOFI's ability to sustain top-line expansion and improve cash flow generation. Near-term catalysts include Q2 2026 earnings on July 29, where management guides for 30% revenue growth. Key risks involve persistent cash burn, competitive intensity in fintech, and sensitivity to interest rate changes. The stock offers upside to consensus targets if execution remains strong.